Published in JAMA on March 21, 2007
Physician attitudes toward industry: a view across the specialties. Arch Surg (2010) 2.29
Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ (2010) 2.05
Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health (2011) 1.46
Limiting the influence of pharmaceutical industry gifts on physicians: self-regulation or government intervention? J Gen Intern Med (2009) 1.04
Orthopaedic Surgeons Receive the Most Industry Payments to Physicians but Large Disparities are Seen in Sunshine Act Data. Clin Orthop Relat Res (2015) 1.01
Sunshine laws and the pharmaceutical industry. JAMA (2007) 0.97
Show us the money: lessons in transparency from state pharmaceutical marketing disclosure laws. Health Serv Res (2009) 0.94
Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med (2009) 0.93
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ (2016) 0.81
Effect of physician payment disclosure laws on prescribing. Arch Intern Med (2012) 0.80
Growth hormone and health policy. J Clin Endocrinol Metab (2010) 0.78
Interventions to reduce corruption in the health sector. Cochrane Database Syst Rev (2016) 0.75
Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation. Isr J Health Policy Res (2017) 0.75
Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA (2008) 12.36
Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA (2008) 8.60
Delayed time to defibrillation after in-hospital cardiac arrest. N Engl J Med (2008) 8.36
Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med (2006) 8.18
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Are racial and ethnic minorities less willing to participate in health research? PLoS Med (2005) 7.88
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med (2009) 6.89
Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol (2014) 6.62
Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study. Lancet (2012) 6.60
Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ (2012) 6.39
An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes (2008) 6.00
The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med (2005) 5.86
Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med (2002) 5.74
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med (2005) 5.49
Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA (2013) 5.27
National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA (2011) 5.16
Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA (2003) 5.09
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA (2002) 4.92
Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med (2002) 4.80
National trends in use of computed tomography in the emergency department. Ann Emerg Med (2011) 4.72
The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med (2008) 4.70
Regulatory review of novel therapeutics--comparison of three regulatory agencies. N Engl J Med (2012) 4.50
Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med (2002) 4.45
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
Consequences of inadequate sign-out for patient care. Arch Intern Med (2008) 4.39
Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA (2003) 4.38
Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA (2010) 4.36
Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation (2006) 4.35
Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA (2009) 4.29
Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol (2004) 4.14
Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol (2011) 4.07
Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Time to treatment in primary percutaneous coronary intervention. N Engl J Med (2007) 3.95
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol (2006) 3.85
When choosing statin therapy: the case for generics. JAMA Intern Med (2013) 3.80
Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation (2005) 3.78
Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2012) 3.72
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45
Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA (2004) 3.45
Transfers of patient care between house staff on internal medicine wards: a national survey. Arch Intern Med (2006) 3.43
Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med (2008) 3.42
Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA (2006) 3.40
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J (2004) 3.37
Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA (2010) 3.36
Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009. J Clin Oncol (2012) 3.34
Recent declines in hospitalizations for acute myocardial infarction for Medicare fee-for-service beneficiaries: progress and continuing challenges. Circulation (2010) 3.32
Hospital variation in time to defibrillation after in-hospital cardiac arrest. Arch Intern Med (2009) 3.27
Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J (2005) 3.26
Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med (2013) 3.26
Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation (2008) 3.19
Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol (2003) 3.19
Achieving rapid door-to-balloon times: how top hospitals improve complex clinical systems. Circulation (2006) 3.16
Contemporary evidence about hospital strategies for reducing 30-day readmissions: a national study. J Am Coll Cardiol (2012) 3.12
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J (2003) 3.11
The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med (2006) 3.09
Assessing the impact of a cooperative group trial on breast cancer care in the medicare population. J Clin Oncol (2012) 3.07
Recruiting vulnerable populations into research: a systematic review of recruitment interventions. J Gen Intern Med (2007) 3.02
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. Arch Intern Med (2012) 2.95
Impact of race on the professional lives of physicians of African descent. Ann Intern Med (2007) 2.92
Hospital strategies for reducing risk-standardized mortality rates in acute myocardial infarction. Ann Intern Med (2012) 2.86
Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med (2004) 2.84
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
Opening of specialty cardiac hospitals and use of coronary revascularization in medicare beneficiaries. JAMA (2007) 2.81
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med (2009) 2.80